- BriaCell’s new patent protects its novel personalized off-the-shelf cell-based technology for breast cancer and multiple other cancer indications until 2040.
- BriaCell expects to initiate its Bria-OTS™ clinical study under an Investigational New Drug Application (IND) in the first half of 2023, in accordance with FDA guidance.
- Two additional clinical sites are now active in Phase II Bria-IMT™ study to broaden patient access:
Carle Cancer Institute inUrbana, Illinois and theAmerican Oncology Network, LLC (AON) inBaltimore, Maryland .
“We are extremely excited with the new patent for our novel personalized off-the-shelf cancer immunotherapy technology, which provides patent protection for the Bria-OTS™ immunotherapy cell lines under development and further validates and extends our whole-cell cancer immunotherapy technology. This is particularly important because the patent protection is not for one single type of cancer, but rather applies to multiple cancer indications,” stated Dr.
Intellectual Property: US Patent No. 11,559,574, titled “Whole-cell cancer vaccines and methods for selection thereof,” will issue on
Additionally, BriaCell was awarded Australian Patent No. 2017224232, titled “Whole-cell cancer vaccines and methods for selection thereof,” for claims covering composition of matter and method of use for BriaCell’s whole-cell immunotherapy for cancer in
BriaCell currently holds multiple issued patents and pending patent applications to cover its whole-cell immunotherapy’s composition of matter and method of use worldwide. For a summary of BriaCell’s issued patents, please visit https://briacell.com/patents/.
Bria-OTS™ Program Timelines: FDA has provided guidance regarding the development of cells and final cell-bank testing for BriaCell’s Bria-OTS™ clinical-grade cell lines. Once completed in accordance with FDA’s requirements, BriaCell expects to initiate the Bria-OTS™ study under an Investigational New Drug Application (IND) in the first half of 2023.
Additional Clinical Sites: BriaCell is pleased to announce that it has added
The following clinical sites are actively enrolling patients for BriaCell’s ongoing Phase II combination study:
Carle Cancer Institute ,Urbana, Illinois American Oncology Network, LLC (AON),Baltimore, Maryland - Mayo Clinic,
Jacksonville, Florida - Hoag,
Newport Beach, California Sylvester Comprehensive Cancer Center , part of UHealth – theUniversity of Miami Health System ,Miami, Florida Atlantic Health System ,Morristown and Overlook Hospitals,Morristown andSummit, New Jersey Tranquil Clinical Research ,Webster, Texas Mary Crowley Cancer Research center,Dallas, Texas Providence Medical Group ,Santa Rosa, California Cancer Center of Kansas ,Wichita, Kansas
About
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes regarding the initiation of the Company's Bria-OTS™ clinical study under an Investigational New Drug Application in the first half of 2023; the ability to treat patients more rapidly with pre-made personalized immunotherapies; the potential ability to significantly improve survival outcomes in late-stage cancer patients; and the potential patent term extension under Hatch-Waxman. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the
Neither the
Contact Information
Company Contact:
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
![](https://ml.globenewswire.com/media/NDA2MWExMDktMzA1Mi00OTNiLTlkODgtOTJiZDYwZDJjNGJkLTExMDIyMjk=/tiny/BriaCell-Therapeutics-Corp-.png)
2023 GlobeNewswire, Inc., source